Ayala Pharmaceuticals Inc. (AYLA): Price and Financial Metrics
GET POWR RATINGS... FREE!
AYLA Stock Summary
- AYLA's went public 1.72 years ago, making it older than merely 3.4% of listed US stocks we're tracking.
- For AYLA, its debt to operating expenses ratio is greater than that reported by just 0.39% of US equities we're observing.
- AYLA's price/sales ratio is 24.32; that's higher than the P/S ratio of 93.54% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Ayala Pharmaceuticals Inc are VBLT, GNCA, PIRS, SYBX, and ALT.
- Visit AYLA's SEC page to see the company's official filings. To visit the company's web site, go to www.ayalapharma.com.
AYLA Valuation Summary
- AYLA's price/sales ratio is 49.4; this is 1200% higher than that of the median Healthcare stock.
- Over the past 16 months, AYLA's price/sales ratio has gone down 28.6.
- AYLA's EV/EBIT ratio has moved up 6.1 over the prior 16 months.
Below are key valuation metrics over time for AYLA.
AYLA Stock Price Chart Interactive Chart >
AYLA Price/Volume Stats
|Current price||$5.52||52-week high||$28.68|
|Prev. close||$5.87||52-week low||$5.40|
|Day high||$6.00||Avg. volume||47,079|
|50-day MA||$8.47||Dividend yield||N/A|
|200-day MA||$10.41||Market Cap||76.92M|
Ayala Pharmaceuticals Inc. (AYLA) Company Bio
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.
Most Popular Stories View All
AYLA Latest News Stream
|Loading, please wait...|
AYLA Latest Social Stream
View Full AYLA Social Stream
Latest AYLA News From Around the Web
Below are the latest news stories about Ayala Pharmaceuticals Inc that investors may wish to consider to help them evaluate AYLA as an investment opportunity.
Let’s not beat about the bush too much. At the end of the day every investor wants to see a strong return on their outlay. The stronger, the better. The thing is, the markets are predicated on a simple equation. Go with the safer bets, i.e. the mega-caps, and you will probably make bank, although less likely to see enormous gains. On the other hand, take a chance on a smaller, less established name and the rewards could be far grander. However, there’s a catch; this is a risky play and you are far more likely to see the investment evaporate when placing a bet on the wrong horse.
REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the H.C. Wainwright BioConnect Virtual Conference, taking place on January 10-13, 2022. A webcast of the presentation will be ava
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Ayala Pharmaceuticals (AYLA – Research Report) today and set a price target of $18.00. The company's shares closed last Tuesday at $8.95, close to its 52-week low of $7.74. According to TipRanks.com, Selvaraju 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -18.5% and a 25.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ayala Pharmaceuticals with a $19.00 average price target.
-- Data read-outs expected on AL102 in desmoid tumors and AL101 in ACC and TNBC --REHOVOT, Israel and WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced its key objectives for 2022. “We believe that 2022 will be a pivotal ye
Zacks Investment Research downgraded shares of Ayala Pharmaceuticals (NASDAQ:AYLA) from a buy rating to a hold rating in a research report released on Tuesday morning, Zacks.com reports. According to Zacks, Ayala Pharmaceuticals Inc. is a clinical-stage oncology company. It focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. 
AYLA Price Returns